RNA-based method for predicting onset of immune-related adverse events induced by cancer immunotherapy agent

By integrating genetic, molecular, and cellular data to analyze neutrophil scores and immune cell profiles, the method effectively predicts immune-related adverse reactions induced by RNA-based immunotherapy, addressing the limitations of existing approaches and improving patient management and cost-effectiveness.

WO2024232703A1PCT designated stage expired Publication Date: 2024-11-14THE ASAN FOUND +2

Patent Information

Application Number
PCT/KR2024/006293
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-09
Filing Date
2024-05-09
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Current methods for predicting immune-related adverse reactions (irAEs) induced by RNA-based immunotherapy are limited by their focus on specific drugs, cancer types, and biomarkers that are influenced by non-tumor-related factors, lacking a comprehensive understanding of genetic, molecular, and cellular risk factors.

Method used

A method that integrates genetic, molecular, and cellular data to measure gene expression and detect neutrophil scores and immune cell profiles in biological samples, using techniques like RNA sequencing and machine learning models to predict the onset of irAEs across various cancer types and immunotherapy agents.

Benefits of technology

This approach provides a robust biomarker for predicting irAEs, enhancing the ability to identify patients at risk before and during treatment, thereby improving patient management and reducing medical costs by accurately forecasting adverse reactions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024006293_14112024_PF_FP_ABST
    Figure KR2024006293_14112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to an RNA-based method for predicting the onset of immune-related adverse events induced by a cancer immunotherapy agent. In the present invention, as a result of analyzing various factors related to the onset of immune-related adverse events induced by a cancer immunotherapy agent, it was confirmed that gene expression-based neutrophil quantitative values or immune cell profiles are closely related to the onset of immune-related adverse events. Accordingly, the neutrophil quantitative values or immune cell profiles are expected to be useful as a biomarker for predicting the onset of immune-related adverse events induced by a cancer immunotherapy agent or predicting reactivity to the cancer immunotherapy agent.
Need to check novelty before this filing date? Find Prior Art

Description

Method for predicting the onset of immune-related adverse reactions induced by RNA-based immunotherapy

[0001] The present invention relates to a method for predicting the onset of immune-related adverse reactions induced by RNA-based immunotherapy.

[0002] This application claims priority to Korean Patent Application No. 10-2023-0060147, filed May 9, 2023, the entire disclosure of which is incorporated herein by reference.

[0003]

[0004] Immune checkpoint blockade (ICB) therapy has become a major treatment for various cancer types, and its role has expanded from the adjuvant setting to the neoadjuvant setting due to immune-related adverse events (irAEs) following ICB treatment. While most early-stage or low-grade irAEs can be managed with corticosteroids or immunosuppressants, some irAEs can be fatal or cause permanent morbidity if not promptly detected and treated. Therefore, predicting the occurrence of irAEs before (pre-treatment (PRE)) or early during treatment (EDT) of ICB therapy is clinically crucial not only for patient management but also for healthcare costs. Furthermore, irAEs offer an opportunity to understand how autoimmunity develops in response to immune activators.

[0005] Previous irAE studies have primarily focused on clinical or biochemical characteristics measured in peripheral blood. While complete blood counts (CBCs) have been extensively studied, several studies have yielded conflicting results, suggesting that CBC-based biomarkers are susceptible to non-tumor-related factors, such as patient clinical status and medical history. Cytokine profiles have also been proposed as predictors of irAEs. For example, IL-6 suppresses the differentiation of regulatory T and B cells and contributes to overactivation of the adaptive immune system, and clonal expansion of CD8+ T cells in the peripheral blood has been associated with the development of severe irAEs in patients treated with ipilimumab.

[0006] Apart from peripheral blood measurements, tumor mutation burden has been proposed as a predictor of irAE occurrence in an attempt to explain the relatively high incidence of irAEs in lung cancer and melanoma. However, mutation burden may act as a confounding factor, indirectly increasing the risk of irAEs by promoting treatment response to ICB. Furthermore, analysis of TCGA multi-omics data identified LCP1 and ADPGK as predictive biomarkers of irAEs; however, validation of their predictive power was limited to a limited number of lung cancer patients, comparing 14 irAE samples to 14 control samples. Both studies relied on data from the FDA Adverse Event Reporting System (FAERS), a database not specifically designed to study ICB-associated irAEs. For germline mutations, polygenic risk scores derived from genome-wide association studies were applied to atezolizumab-induced skin or thyroid-related irAEs.

[0007] That is, genetic, molecular, and cellular risk factors for irAEs remain elusive and require integrated analysis, and the diversity of irAE pathology suggests a multifaceted complexity of underlying mechanisms, necessitating a much more comprehensive investigation. However, most previous irAE studies have been limited to specific drugs (e.g., ipilimumab or atezolizumab), irAE symptoms (e.g., cutaneous autoimmunity), and cancer types (e.g., lung cancer or melanoma), often utilizing a limited number of irAE samples.

[0008] Accordingly, the present invention aims to provide a biomarker for predicting the onset of irAEs induced by immunotherapy such as ICB and a method for predicting the onset of irAEs using the same by performing a comprehensive analysis of irAEs by integrating multidimensional data including genetic factors, molecular and cellular profiles of immune cells, laboratory data, and clinical variables before and after ICB treatment in hundreds of patients with various types of irAEs.

[0009]

[0010] The present inventors analyzed genetic factors, molecular and cellular profiles of immune cells, laboratory data, and clinical variables related to the onset of irAE before and after ICB treatment, and confirmed a correlation between gene expression-based neutrophil quantitative values ​​(Neutrohil score) and immune cell profiles and the onset of irAE, and completed the present invention based on this.

[0011] Accordingly, the purpose of the present invention is to provide a method for providing information for predicting the onset of an immune-related adverse reaction induced by an immunotherapy agent, comprising the steps of measuring the expression of a gene in a biological sample isolated from a subject; and the step of detecting at least one selected from the group consisting of a neutrophil score and an immune cell profile.

[0012] Another object of the present invention is to provide a composition and kit for predicting the onset of an immune-related adverse reaction induced by an immunotherapy agent, the composition comprising an agent for detecting at least one selected from the group consisting of a neutrophil score and an immune cell profile.

[0013]

[0014] However, the technical problems to be solved by the present invention are not limited to the problems mentioned above, and other problems not mentioned can be clearly understood by a person having ordinary skill in the technical field to which the present invention belongs from the description below.

[0015]

[0016] In order to achieve the above-mentioned purpose, the present invention provides a method for providing information for predicting the onset of an immune-related adverse reaction induced by an immunotherapy agent, comprising the steps of: measuring the expression of a gene in a biological sample isolated from a subject; and detecting at least one selected from the group consisting of a neutrophil score and an immune cell profile.

[0017] In addition, the present invention provides a method for providing information for predicting responsiveness to an immunotherapy agent, comprising the steps of: measuring the expression of a gene in a biological sample isolated from a subject; and detecting at least one selected from the group consisting of a neutrophil score and an immune cell profile.

[0018] As one embodiment of the present invention, the expression of the gene can be measured through one or more methods selected from the group consisting of sequencing, RNA sequencing, and next generation sequencing (NGS), but is not limited thereto.

[0019] In another embodiment of the present invention, the immune cell profile comprises neutrophils, natural killer T cells (NKT), type 1 regulatory T cells (Tr1), type 1 helper T cells (Th1), induced regulatory T cells (iTreg), central memory T cells (Tcm), and CD4 + Naive T cells (CD4 + The amount of one or more selected from the group consisting of, but not limited to, naive T cells, effector memory T cells (Tem), and cytotoxic T cells (Cytotoxic T cells (Tc).

[0020] As another embodiment of the present invention, the subject may be a cancer patient before or after receiving immunotherapy, but is not limited thereto.

[0021] As another embodiment of the present invention, the biological sample may be one or more selected from the group consisting of tissue, cells, whole blood, serum, plasma, saliva, sputum, cerebrospinal fluid, urine, and feces isolated from a subject, but is not limited thereto.

[0022] In another embodiment of the present invention, the immune-related adverse reaction may be at least one selected from the group consisting of skin adverse reactions, endocrine system adverse reactions, thyroid gland adverse reactions, musculoskeletal system adverse reactions, gastrointestinal system adverse reactions, neurologic system adverse reactions, flu-like symptoms, and pneumonia caused by an immunotherapy agent, but is not limited thereto.

[0023] As another embodiment of the present invention, the method may further include, but is not limited to, a step of predicting that the risk of developing an immune-related adverse reaction is high when at least one selected from the group consisting of a neutrophil score, an amount of neutrophils in an immune cell profile, and an amount of cytotoxic T cells in an immune cell profile is lower than that in a control group in a biological sample isolated from a subject.

[0024] In another embodiment of the present invention, the method comprises the steps of: isolating natural killer T cells (NKT), type 1 regulatory T cells (Tr1), type 1 helper T cells (Th1), induced regulatory T cells (iTreg), central memory T cells (Tcm), and CD4 from a biological sample isolated from a subject; and + Naive T cells (CD4 +The present invention may further include, but is not limited to, a step of predicting that the risk of developing an immune-related adverse reaction is high when the amount of one or more selected from the group consisting of naive T cells, effector memory T cells (Tem), and effector memory T cells (Tem) is higher than that of the control group.

[0025] As another embodiment of the present invention, the method may further include, but is not limited to, a step of detecting at least one selected from the group consisting of a neutrophil score and an immune cell profile to predict the risk of developing an immune-related adverse reaction induced by an immunotherapy agent through a machine learning-based model.

[0026] As another embodiment of the present invention, the machine learning-based model may be one or more selected from the group consisting of XGBoost and Random forest, but is not limited thereto.

[0027] In addition, the present invention provides a composition for predicting the onset of an immune-related adverse reaction induced by an immunotherapy agent, comprising an agent for detecting at least one selected from the group consisting of a neutrophil score and an immune cell profile.

[0028] As one embodiment of the present invention, the agent for detecting the neutrophil quantitative value may include, but is not limited to, a primer or probe that specifically binds to a set of neutrophil mediated immunity pathway genes.

[0029] In another embodiment of the present invention, the agent for detecting the immune cell profile is neutrophil, natural killer T cell (NKT), type 1 regulatory T cell (Tr1), type 1 T helper T cell (Th1), induced regulatory T cell (iTreg), central memory T cell (Tcm), CD4 + Naive T cells (CD4 + The invention may include, but is not limited to, primers or probes that specifically bind to a set of marker genes for one or more immune cells selected from the group consisting of naive T cells, effector memory T cells (Tem), and cytotoxic T cells (Tc).

[0030] In addition, the present invention provides a kit for predicting the onset of immune-related adverse reactions induced by an immunotherapy agent, comprising the composition.

[0031] In addition, the present invention provides a composition comprising an agent for detecting at least one selected from the group consisting of a neutrophil score and an immune cell profile, for use in predicting the onset of an immune-related adverse reaction induced by an immunotherapy agent.

[0032] In addition, the present invention provides a use for preparing a formulation for predicting the onset of an immune-related adverse reaction induced by an immunotherapy agent, wherein the formulation detects at least one selected from the group consisting of a neutrophil score and an immune cell profile.

[0033]

[0034] In the present invention, various factors related to the development of immune-related adverse reactions induced by immunotherapy-based anticancer drugs were analyzed. Results revealed that gene expression-based neutrophil quantification or immune cell profiles were closely associated with the development of immune-related adverse reactions. Therefore, it is expected that the neutrophil quantification or immune cell profiles can be useful as biomarkers for predicting the development of immunotherapy-based immune-related adverse reactions or predicting responsiveness to immunotherapy-based anticancer drugs.

[0035]

[0036] FIG. 1 is a diagram showing cell type abundance confirmed by PCA analysis in whole blood RNA-seq data according to one embodiment of the present invention.

[0037] FIG. 2 is a diagram confirming the correlation between the quantitative values ​​of neutrophils before treatment (PRE) and early after treatment (EDT) and the occurrence of immune-related adverse reactions induced by an immunotherapy agent according to one embodiment of the present invention.

[0038] Figure 3 is a diagram comparing the expression levels of neutrophil marker genes between irAE and control groups in PRE and EDT patient samples according to one embodiment of the present invention. *P<0.05, **P<0.01, ***P<0.001.

[0039] FIG. 4 is a diagram illustrating genes differentially expressed between irAE and control groups in PRE and EDT patient samples according to one embodiment of the present invention using a volcano plot.

[0040] FIG. 5 is a diagram showing the results of pathway enrichment analysis for genes underexpressed in irAE in PRE and EDT patient samples according to one embodiment of the present invention.

[0041] FIG. 6 is a diagram showing the degree of pathway enrichment for genes underexpressed in irAE for 12 irAE types in PRE and EDT patient samples according to one embodiment of the present invention.

[0042] FIG. 7 is a diagram confirming the correlation between immune cell profiles and the development of immune-related adverse reactions induced by immunotherapy in PRE and EDT patient samples according to one embodiment of the present invention.

[0043] FIG. 8 is a diagram showing the AUC of a training set and a test set for predicting the occurrence of immune-related adverse reactions induced by immunotherapy using XGBoost and Random forest in PRE and EDT patient samples according to one embodiment of the present invention.

[0044] FIG. 9 is a diagram confirming the feature importance of XGBoost learned on PRE and EDT patient samples according to one embodiment of the present invention.

[0045]

[0046] In one experimental example of the present invention, 68 types of irAEs were identified in 276 out of 531 patients treated with ICB, among which skin was the most frequent irAE type (26%), followed by influenza-like (21%) and multiple (all grades) (18%) (see Experimental Example 1).

[0047] In another experimental example of the present invention, RNA sequencing was performed on 531 matched whole blood samples before (PRE) and at the beginning of treatment (EDT) with ICB. The results showed that neutrophil counts were lower in patients who developed irAEs, and this trend was more evident in the post-treatment (EDT) samples. In addition, immune cell types significantly associated with the occurrence of irAEs were identified, and this trend was more evident in the post-treatment (EDT) samples (see Experimental Example 2).

[0048] In another experimental example of the present invention, an RNA-based irAE prediction model was established and verified using XGBoost and Random forest for samples before (PRE) and after (EDT) immunotherapy treatment. As a result, the test AUC values ​​of the model created by XGBoost were 0.66 and 0.78 in the samples before and after treatment, respectively, and the test AUC values ​​of the model created by Random forest were 0.67 and 0.72 in the samples before and after treatment, respectively. When the importance of the neutrophil quantitative value and the immune cell profile features was confirmed in the XGBoost model, it was confirmed that cytotoxic T cells were the most important feature before treatment, and neutrophils were the most important feature after treatment (see Experimental Example 3).

[0049]

[0050] Hereinafter, the present invention will be described in detail.

[0051]

[0052] The present invention provides a method for providing information for predicting the onset of an immune-related adverse reaction induced by an immunotherapy agent, comprising the steps of measuring the expression of a gene in a biological sample isolated from a subject; and detecting at least one selected from the group consisting of a neutrophil score and an immune cell profile.

[0053] In addition, the present invention provides a method for predicting the onset of an immune-related adverse reaction induced by an immunotherapy agent, comprising the steps of: measuring the expression of a gene in a biological sample isolated from a subject; and detecting at least one selected from the group consisting of a neutrophil score and an immune cell profile.

[0054] In the present invention, "immunotherapy" refers to a drug that enhances the body's own immune system and thus its ability to fight cancer. Because immunotherapy agents treat cancer by strengthening the patient's own immune system, they have fewer side effects, improve the quality of life of cancer patients, and significantly extend survival. Immunotherapy agents exhibit anticancer effects by enhancing the specificity, memory, and adaptability of the immune system. Immunotherapy agents include, but are not limited to, agents for immune checkpoint blockade (ICB), immune cell therapy agents, therapeutic antibodies, and immune checkpoint enhancers. In the present invention, the agent for blocking the immune checkpoint, i.e., the immune checkpoint inhibitor, unlike existing immunotherapeutic agents (cytokine therapeutic agents, anticancer vaccines, etc.), has a mechanism of preventing the formation of an immunological synapse by binding to the binding site of cancer cells and T cells to block immune evasion signals, thereby allowing T cells that are not immune evasion interference to destroy cancer cells, and may be, for example, one or more selected from the group consisting of nivolumab, atezolizumab, pembrolizumab, duvalumab, avelumab, ipilimumab, and tremelimumab, but is not limited thereto.

[0055] In the present invention, “immune-related adverse event (irAE)” refers to various adverse reactions that occur due to immunotherapy treatment, including inflammatory reactions that occur in connection with activation of the autoimmune system.

[0056] In the present invention, the immune-related adverse reaction may be at least one selected from the group consisting of skin adverse reactions, endocrine system adverse reactions, thyroid gland adverse reactions, musculoskeletal system adverse reactions, gastrointestinal system adverse reactions, neurologic system adverse reactions, flu-like symptoms, and pneumonia caused by an immunotherapy agent, but is not limited thereto. According to one embodiment or experimental example of the present invention, the immune-related adverse reaction may exhibit two or more symptoms together, and the severity thereof may be divided into three grades. For example, in the present invention, if there are three or more types of immune-related adverse reactions according to the severity of the immune-related adverse reactions, it is indicated as 'Multiple G>=1', if there are three or more types of grade 2 or higher, it is indicated as 'Multiple G>=2', if there are any types of grade 3 or higher and any types of grade 2 or higher, it is indicated as 'Critical', and if there are any types of grade 2 or higher, it can be indicated as 'Any'.

[0057] In the present invention, “detection” includes both measuring and confirming the presence (expression) of a target substance, or measuring and confirming a change in the presence level (expression level) of a target substance. In the same context, detecting the neutrophil quantitative value or immune cell profile in the present invention means measuring the presence (i.e., measuring the presence or absence) of neutrophil-mediated immune pathway genes, neutrophils, or immune cells, or measuring the qualitative and quantitative change levels of the neutrophil-mediated immune pathway genes, neutrophils, or immune cells. The measurement can be performed without limitation, including both qualitative methods (analysis) and quantitative methods. The types of qualitative and quantitative methods for measuring the presence or absence of neutrophil-mediated immune pathway genes, neutrophils, or immune cells are well known in the art, and the experimental methods described herein are included therein.

[0058] In the present invention, the “subject” may include a cancer patient who wishes to receive immunotherapy, i.e., a cancer patient before receiving immunotherapy or a cancer patient after receiving immunotherapy, and the cancer patient after receiving immunotherapy may be an early-stage cancer patient after receiving immunotherapy, but is not limited thereto.

[0059] In the present invention, the “control group” may be a normal person or a cancer patient who has not exhibited an immune-related adverse reaction after receiving immunotherapy, and according to one embodiment of the present invention, the control group may be a cancer patient who has not exhibited an immune-related adverse reaction after receiving immunotherapy, but is not limited thereto.

[0060] In the present invention, the cancer may be at least one selected from the group consisting of lung cancer including non-small cell lung cancer and small cell lung cancer, esophageal cancer, hepatocellular carcinoma, gastric cancer, breast cancer, bladder cancer, kidney cancer, biliary tract cancer, urethral cancer, head and neck cancer, melanoma, colon cancer, gallbladder cancer, pancreatic cancer, ampulla of Vater cancer, neuroendocrine carcinoma, paraganglioma, ovarian cancer, uterine cancer, prostate cancer, thymic cancer, and cerebral angiosarcoma, but is not limited thereto.

[0061] In the present invention, the biological sample may be at least one selected from the group consisting of tissue, cells, whole blood, serum, plasma, saliva, sputum, cerebrospinal fluid, urine, and feces separated from a subject, and according to one embodiment or experimental example of the present invention, may be whole blood, but is not limited thereto.

[0062] In the present invention, the step of measuring gene expression can be performed using a conventional method known in the art, and for example, can be performed using one or more methods selected from the group consisting of sequencing, RNA sequencing, and next generation sequencing (NGS), but is not limited thereto.

[0063] In the present invention, the gene expression refers to a value quantified by comparing the read obtained from RNA sequencing with a human standard reference genome, and according to one embodiment of the present invention, the human standard reference genome may be GRCh37 (hg19), but is not limited thereto.

[0064] In the present invention, the neutrophil quantitative value (Neurophil score) can be measured using a method known in the art, and for example, the neutrophil quantitative value can mean a value quantified and standardized through a single sample gene set enrichment analysis (ssGSEA) using the neutrophil mediated immunity pathway (GO:0002446) gene set provided by Gene Ontology (http: / geneontology.org / ) based on gene expression, but is not limited thereto. At this time, the value quantified for the neutrophil-mediated immune pathway gene set may be the total gene expression amount quantified by confirming the integrated expression of the gene set, and quantification and standardization may be calculated by the method of ssGSEA (Barbie et al, Nature, 2009, PMID: 19847166., genepattern.org / modules / docs / ssGSEAProjection / 5#gsc.tab=0).

[0065] In the present invention, the immune cell profile is neutrophil, natural killer T cell (NKT), type 1 regulatory T cell (Tr1), type 1 helper T cell (Th1), induced regulatory T cell (iTreg), central memory T cell (Tcm), CD4 + Naive T cells (CD4 +The immune cell profile may be a value measuring one or more amounts selected from the group consisting of naive T cells, effector memory T cells (Tem), and cytotoxic T cells (Cytotoxic T cells (Tc), but is not limited thereto. In the present invention, the immune cell profile may be measured using a method known in the art, for example, it may be measured from ImmucellAI (Miao, Y et al., Adv. Sci. 7, 1902880., http: / bioinfo.life.hust.edu.cn / ImmuCellAI), but is not limited to the type as long as it is a method capable of measuring the immune cell profile.

[0066] In the present invention, the immune cell profile can be measured by quantifying the total gene expression amount of the immune cell marker gene set provided by ImmucellAI, and the marker gene set for each immune cell is as follows:

[0067] Marker genes for neutrophils: IL18RAP, BMX, BTNL8, CASP5, CLC, CXCR1, CXCR2, FCGR3B, FPR2, HSPA6, MEFV, PADI4, S100A12, TREML2, TRPM6, SIGLEC5, CREB5, ALPL, AATK, CEACAM3, CSF2RB, CSF3R, FBXO38, MAK, PAK2, TOP1, UBXN2B, and VNN3.

[0068] Marker genes for natural killer T cells (NKT): CASP5, DOLK, GMIP, PRR5L, SGCA, SLAMF1, TCOF1, TGFBR2.

[0069] Marker genes for type 1 regulatory T cells (Tr1): TNFRSF4, CD4, CCR4, CD28, and LAX1.

[0070] Marker genes for type 1 helper T cells (Th1): IFNG, IL2, MNAT1, SLAMF1, STAT1, EIF2B2, APBB2, CCL4, CTLA4, GGT1, LTA, SYNGR3, and TACO1.

[0071] Marker genes for induced regulatory T cells (iTreg): FOXP3, STAT5A, CCR8, CD5, HS3ST3B1, TTN, CTLA4, FASLG, ICOS, CCR3, GALNT8, NFATC3, SIT1, CD28, IL10RA, PPM1B, ATG2B, CCR4, and ZFYVE9.

[0072] Marker genes for central memory T cells (Tcm): CORO7, ATM, GMEB2, SNRPN, ADSL, ITK, TFAP4, NAA16, LY9, CYLD, GIMAP4, PURA, DVL1, RPP38, LRIG2, IL7R, CDKN2AIP, APBB1, IPCEF1, CD247, CD40LG, TRADD, CD3E, TPR, ARID5B, UBASH3A, NCK1, SPTAN1, GPR171, and CD5.

[0073] CD4 + Naive T cells (CD4 + Marker genes for naive T cells: CD2, CD3G, CD4, GIMAP6, GLG1, HMOX2, IL7R, ITK, LIMD2, LY9, NAA16, OBSCN, PACS1, PLCL1, RPL14, SNPH, TPP2, TRAF1, ZBTB40, CD40LG, and SEPT9.

[0074] Marker genes for effector memory cells (Tem): APBA3, CD160, CD2, CD8B, CDK10, CDKN2AIP, CHST12, COG4, CX3CR1, DHX16, EWSR1, GIMAP6, GPR171, GZMK, HOMX2, IKZF3, ITK, KLRD1, KLRG1, MAPKAPK5, MORC2, MRFAP1L1, PLCG1, PSMC5, RNF167, SBF1, SF3B2, SLAMF1, TBCD, USP47, ZFYVE9, and ZNF549.

[0075] Marker genes for cytotoxic T cells (Tc): KNG1, PSORS1C2, BLNK, SCN3A, TNFRSF10C, ITGAM, KLRK1, CD8A, GNLY, GZMH, PTGDR2, CD8B, GZMA, and PRF1.

[0076] In the present invention, the method may further include, but is not limited to, a step of predicting that the risk of developing an immune-related adverse reaction is high when at least one selected from the group consisting of a neutrophil score, the amount of neutrophils in an immune cell profile, and the amount of cytotoxic T cells in an immune cell profile is lower than that in a control group in a biological sample isolated from a subject, compared to a control group.

[0077] In the present invention, the method is to identify natural killer T cells (NKT), type 1 regulatory T cells (Tr1), type 1 helper T cells (Th1), induced regulatory T cells (iTreg), central memory T cells (Tcm), and CD4 among the immune cell profiles in a biological sample isolated from a subject. + Naive T cells (CD4 +The present invention may further include, but is not limited to, a step of predicting that the risk of developing an immune-related adverse reaction is high when the amount of one or more selected from the group consisting of naive T cells, effector memory T cells (Tem), and effector memory T cells (Tem) is higher than that of the control group.

[0078] In the present invention, the method may further include, but is not limited to, a step of detecting at least one selected from the group consisting of a neutrophil score and an immune cell profile and predicting the risk of developing an immune-related adverse reaction induced by an immunotherapy agent through a machine learning-based model.

[0079] In the present invention, the machine learning-based model may be one or more selected from the group consisting of XGBoost and random forest, but is not limited thereto.

[0080] In the present invention, "XGBoost" stands for Extreme Gradient Boosting, a type of ensemble boosting technique. It forms a model by sequentially compensating for errors in previous models. The error (loss) between actual and predicted values ​​in the previous model is input into the training data, and the gradient is used to compensate for the errors.

[0081] In the present invention, “random forest” is a type of ensemble learning method used for classification, regression analysis, etc., and operates by outputting a class (classification) or average prediction value (regression analysis) from a plurality of decision trees constructed during the training process.

[0082]

[0083] In addition, the present invention provides a method for providing information for predicting responsiveness to an immunotherapy agent, comprising the steps of: measuring the expression of a gene in a biological sample isolated from a subject; and detecting at least one selected from the group consisting of a neutrophil score and an immune cell profile.

[0084] In addition, the present invention provides a method for predicting responsiveness to an immunotherapy agent, comprising the steps of: measuring the expression of a gene in a biological sample isolated from a subject; and detecting at least one selected from the group consisting of a neutrophil score and an immune cell profile.

[0085] In the present invention, when at least one selected from the group consisting of the neutrophil score, the amount of neutrophils in the immune cell profile, and the amount of cytotoxic T cells in the immune cell profile in the biological sample separated from the subject is lower than that of the control group, it can be predicted that the responsiveness to the immunotherapy agent will be low, but is not limited thereto.

[0086] In the present invention, among the immune cell profiles in the biological sample separated from the subject, natural killer T cells (NKT), type 1 regulatory T cells (Tr1), type 1 helper T cells (Th1), induced regulatory T cells (iTreg), central memory T cells (Tcm), and CD4 + Naive T cells (CD4 +When the amount of one or more selected from the group consisting of naive T cells, effector memory T cells (Tem), and effector memory T cells (Tem) is higher than that of the control group, it can be predicted that the responsiveness to the immunotherapy agent will be high, but is not limited thereto.

[0087]

[0088] In addition, the present invention provides a composition for predicting the onset of an immune-related adverse reaction induced by an immunotherapy agent, comprising an agent for detecting at least one selected from the group consisting of a neutrophil score and an immune cell profile.

[0089] In the present invention, the formulation is not limited in type as long as it is a formulation capable of detecting a neutrophil quantitative value or an immune cell profile, and may include all formulations used in a method known in the art capable of detecting a neutrophil quantitative value or an immune cell profile. For example, the formulation may include components, compositions, solutions, devices, etc. typically required for a single sample gene set enrichment analysis (ssGSEA) using a neutrophil-mediated immunity pathway gene set provided by Gene Ontology (http: / geneontology.org / ) based on gene expression as a method for detecting a neutrophil quantitative value, and components, compositions, solutions, devices, etc. typically required for ImmucellAI (Miao, Y et al., Adv. Sci. 7, 1902880.) as a method for detecting an immune cell profile. According to one embodiment of the present invention, the agent for detecting the neutrophil quantitative value may include a primer or probe that specifically binds to a set of genes of the neutrophil mediated immunity pathway, and the agent for detecting the immune cell profile ... + Naive T cells (CD4 +The primers or probes may specifically bind to one or more marker genes selected from the group consisting of, but not limited to, naive T cells, effector memory T cells (Tem), and cytotoxic T cells (Tc).

[0090] In the present invention, a "primer" is a short, single-stranded oligonucleotide that serves as the starting point for DNA synthesis. The primer specifically binds to a polynucleotide template under suitable buffer and temperature conditions, and DNA is synthesized by DNA polymerase adding a nucleoside triphosphate having a base complementary to the template DNA to the primer and linking them. Primers typically consist of 15 to 30 base sequences, and the melting temperature (Tm) at which they bind to the template strand varies depending on the base composition and length. The primer sequence need not be completely complementary to a portion of the template base sequence; it is sufficient if it has a length and complementarity suitable for the purpose of amplifying a specific section of mRNA or cDNA through DNA synthesis and measuring the amount of mRNA. Therefore, in the present invention, primer pairs can be easily designed with reference to the base sequence of the cDNA or genomic DNA of the gene or its mRNA. The primers for the above amplification reaction are composed of a set (pair) that complementarily bind to the template (or sense) and the opposite end (antisense) of a specific section of mRNA to be amplified.

[0091] In the present invention, the “probe” refers to a fragment of a polynucleotide such as RNA or DNA, with a length of several to several hundred base pairs, which can specifically bind to mRNA, complementary DNA (cDNA), DNA, etc. of a specific gene, and is labeled so that the presence or absence of the target mRNA or cDNA to which it binds, the expression level, etc. can be confirmed. The selection and hybridization conditions of the probe can be appropriately selected according to techniques known in the art. The probe can be used in a diagnostic method for detecting an allele (or allele). The diagnostic method includes detection methods based on hybridization of nucleic acids, such as Southern blot, and may be provided in a form pre-bound to a substrate of a DNA chip in a method using a DNA chip.

[0092] In the present invention, the primer or probe can be chemically synthesized using a phosphoramidite solid support synthesis method or other widely known methods. In addition, the primer or probe can be variously modified according to methods known in the art, as long as it does not interfere with hybridization with the polynucleotide that is the target to be detected. Examples of such modifications include methylation, capping, substitution with one or more homologs of natural nucleotides, modification between nucleotides, such as uncharged linkers (e.g., methyl phosphonate, phosphotriester, phosphoramidate, carbamate, etc.) or charged linkers (e.g., phosphorothioate, phosphorodithioate, etc.), and binding of labeling materials using fluorescent or enzymes.

[0093] In the present invention, the primer or probe is not limited to a specific sequence as long as it can detect neutrophil quantitative values ​​or immune cell profiles.

[0094] In addition, the present invention provides a kit for predicting the onset of an immune-related adverse reaction induced by an immunotherapy agent or a kit for predicting responsiveness to an immunotherapy agent, comprising the composition.

[0095] In the present invention, the term "kit" refers to a tool that includes a preparation that detects the above-mentioned neutrophil quantitative value or immune cell profile, thereby enabling prediction of the onset of immune-related adverse reactions induced by immunotherapy or prediction of a cancer patient's responsiveness to immunotherapy. In addition to the preparation, the kit of the present invention may also include other components, compositions, solutions, devices, etc. typically required for the measurement or detection methods thereof.

[0096] In the present invention, the kit may include a container; instructions; and a preparation for detecting the neutrophil quantitation value or immune cell profile. The container may serve to package the preparation and may also serve to store and fix the preparation. The material of the container may take the form of, for example, a bottle, a tub, a sachet, an envelope, a tube, an ampoule, etc., and these may be formed partially or wholly from plastic, glass, paper, foil, wax, etc. The container may be initially equipped with a completely or partially detachable stopper, which may be part of the container or may be mechanically, adhesively, or otherwise attached to the container, and may also be equipped with a stopper for allowing access to the contents by means of a syringe needle. The kit may include an outer package, and the outer package may include instructions for the use of the components.

[0097] In addition, the present invention provides a composition comprising an agent for detecting at least one selected from the group consisting of a neutrophil score and an immune cell profile, for use in predicting the onset of an immune-related adverse reaction induced by an immunotherapy agent; or for use in predicting responsiveness to an immunotherapy agent.

[0098] In addition, the present invention provides a use for preparing a formulation for predicting the onset of an immune-related adverse reaction induced by an immunotherapy agent, wherein the formulation detects at least one selected from the group consisting of a neutrophil score and an immune cell profile; or a use for preparing a formulation for predicting responsiveness to an immunotherapy agent.

[0099] In addition, the present invention measures gene expression in RNA obtained from biological samples before and after treatment isolated from subjects suspected of having a high risk of developing an immune-related adverse reaction after immunotherapy treatment of cancer patients or subjects suspected of having a low responsiveness to immunotherapy and a control group, and when at least one low value selected from the group consisting of a neutrophil score, the amount of neutrophils among the immune cell profiles, and the amount of cytotoxic T cells among the immune cell profiles is measured; or when among the immune cell profiles, natural killer T cells (NKT), type 1 regulatory T cells (Tr1), type 1 T helper T cells (Th1), induced regulatory T cells (iTreg), central memory T cells (Tcm), and CD4 + Naive T cells (CD4 +A method for providing information for determining / analyzing whether a subject is highly susceptible to predicting the onset of an immune-related adverse reaction induced by an immunotherapy agent or predicting responsiveness to an immunotherapy agent, wherein the subject is considered to have a high risk of developing an immune-related adverse reaction after immunotherapy treatment or a low responsiveness to an immunotherapy agent when one or more high values ​​selected from the group consisting of naive T cells, and effector memory T cells (Tem) are measured.

[0100] In the present invention, when the term "comprising" is used, it means that other components can be included rather than excluding other components unless specifically stated otherwise. As used throughout the present invention, the terms "step of ~" or "step of ~" do not mean "step for ~."

[0101]

[0102] Hereinafter, preferred examples and experimental examples are presented to aid in understanding the present invention. However, the following examples and experimental examples are provided solely to facilitate a better understanding of the present invention, and the scope of the present invention is not limited by the following examples and experimental examples.

[0103]

[0104] [Example]

[0105] Example 1. Multicenter prospective cohort of patients with immune-related adverse events (irAEs)

[0106] A total of 531 patients, including 276 irAE patients and 255 non-irAE patients who received immune checkpoint blockade (ICB) therapy registered at Seoul Asan Medical Center, were recruited for the study.

[0107] Baseline characteristics of the patient cohort, including patient age, sex, cancer type, and type of ICB treatment administered, are presented in Table 1.

[0108] irAE group (N=276)non-irAE group (N=255)AgeMedian, years (range)64.4 ± 9.962.7 ± 9.9SexMale214 (77.5%)187 (73.3%)Female62 (22.5%)68 (26.7%)Cancer typeGastrointestinal cancer96 (34.8%)56 (22.0%)NSCLC94 (34.1%)102 (40.0%)Urothelial cancer41 (14.9%)41 (16.1%)Pancreatic, hepatic, and biliary cancer32 (11.6%)35 (13.7%)Melanoma5 ( 1.8%)7 ( 2.7%)Breast cancer4 ( 1.4%)1 ( 0.4%)Head and neck cancer2 ( 0.7%)9 ( 3.5%)Other cancer4 ( 1.4%)1 ( 0.4%)Ovary cancer0 ( 0.0%)2 ( 0.8%)ICB type*Nivolumab131 (47.5%)93 (36.5%)Atezolizumab75 (27.2%)84 (32.9%)Pembrolizumab38 (13.8%)64 (25.1%)Nivolumab + Ipilimumab14 ( 5.1%)7 ( 2.7%)Duvalumab8 ( 2.9%)4 ( 1.6%)Ipilimumab1 ( 0.4%)0 ( 0.0%)Investigational Immune checkpoint treatment9 (3.2%)3 (1.2%)ICB treatment regimen*ICB monotherapy231 (83.7%)215 (84.3%)ICB + ICB11 ( 4.0%)7 ( 2.7%)ICB + cytotoxic chemotherapy31 (11.2%)26 (10.2%)ICB + molecular targeted therapy3 ( 1.1%)6 ( 2.4%)ICB+ cytotoxic chemotherapy + molecular targeted therapy0 ( 0.0%)1 ( 0.4%)Treatment setting*Palliative258 (93.5%)240 (94.1%)Maintenance after definitive CRT10 ( 3.6%)11 ( 4.3%)Adjuvant6 ( 2.2%)3 ( 1.2%)Neoadjuvant2 ( 0.7%)1 ( 0.4%)Prior treatment**Cytotoxic chemotherapy178 (65.4%)160 (68.7%)Molecular targeted agent64 (24.2%)46 (20.0%)RT45 (16.5%)52 (22.3%)CRT37 (13.6%)18 ( 7.7%)ECOG performance022 (8.1%)12 ( 4.8%)1221 (81.0%)200 (80.3%)220 ( 7.3%)22 ( 8.8%)>=310 (3.6%)15 (6.0%).

[0109] (irAE, immune-related adverse events; NSCLC, non-small cell lung cancer; ICB, immune checkpoint blockade; RT, radiotherapy; CRT, chemoradiation; ECOG performance, performance status)

[0110]

[0111] Example 2. Classification of irAE patients

[0112] For further analysis and training of the integrated model, 68 types of irAEs (single-label) were classified into 12 primary labels (including the "Any" label). The list of single labels for each of the 12 primary labels is shown in Table 3 of Experimental Example 1 below, and the number of patients for each of the 12 primary labels is shown in Table 4 of Experimental Example 1 below.

[0113]

[0114] Example 3. Clinical characteristics

[0115] Available clinical characteristics for patients in the present cohort included drug type, cancer type, ECOG performance status, history of autoimmune disease, and history of diabetes or hypertension. Pretreatment laboratory tests included a composite of several values ​​calculated from values ​​such as complete blood count (CBC), chemistry, and neutrophil-to-lymphocyte ratio (NLR), with platelet-to-lymphocyte ratio (PLR) also included as a candidate characteristic.

[0116]

[0117] Example 4. RNA sequencing and data processing

[0118] Libraries generated from whole blood samples were sequenced on the Illumina platform as 150-base paired-end reads. The quality of raw FASTQ files was controlled using FastQC (v. 0.11.9), MultiQC (v. 1.9), and Trimmomatic (v. 0.39) (TruSeq3-PE-2.fa:2:30:10:2:keepBothReads LEADING:3 TRAILING:3 MINLEN:36 for adapter sequencing trimming), and SortMeRNA (v. 2.1b) (silva-euk-18s-id95.fasta, silva-euk-28s-id98.fasta) was used for rRNA filtering.

[0119] Reads were aligned to the GRCh37 (hg19) build provided by the 1000 Genomes Project, and genes were assigned based on gencode.v37.annotation.gtf using STAR 2-pass mapping with the --sjdbOverhang 150 option. Aligned reads were classified using SAMtools (v. 1.7), and read counts were calculated using HTSeq (v. 0.12.4). Read counts were normalized by calculating TPM values ​​using house codes.

[0120]

[0121] Example 5. Deconvolution of cell type abundance from RNA-seq data.

[0122] We calculated the abundance of 24 immune cells from whole blood RNA-seq data using ImmuCellAI (Miao, Y et al., Adv. Sci. 7, 1902880). To minimize possible bias between sequencing data from different sequencing batches, we performed PCA analysis (see Figure 1). The PCA plot showed that samples from different sequencing batches formed a coordinated mixture.

[0123]

[0124] Example 6. Designating training and test groups

[0125] The collected cohort was divided into a training group (used for feature discovery and model training associated with irAE occurrence) and a test group (used for model performance validation) in an 8:2 ratio. To ensure unbiased model training and validation, each group was classified based on similar irAE occurrence frequencies.

[0126]

[0127] Example 7. Statistical Test

[0128] To identify features significantly associated with irAE occurrence, the Wilcoxon test was performed. When testing multiple features simultaneously, such as immune cell profiles, p-value adjustment was performed using the FDR method. To determine the final features, features with an FDR value <0.01 for irAE occurrence were selected.

[0129]

[0130] Example 8. Training and Prediction of the Integrated Model

[0131] The integrated model was trained on irAE occurrence. The features of the integrated model included neutrophil counts, which were closely associated with irAE occurrence as described above, as well as immune cell profiles with significant FDR values. The XGBoost framework and the Random Forest framework were implemented to train the integrated model. To train the model, patients with irAEs (true cases) and patients without irAEs (false cases) were divided into training and validation sets in a ratio of 8:2, respectively. All features in the training set were normalized using StandardScaler, and the scaler appropriate for the training set was adopted for feature transformation in the validation set. Since the primary goal was to predict irAE occurrence, the optimal model was selected based on the area under the curve (AUC) value, and the test set, which was not used for model training, was used to validate the model.

[0132]

[0133] Example 9. XGBoost Modeling

[0134] We implemented the XGBoost framework with 5-fold cross validation using Python's XGBoost package. For hyperparameter tuning, the gridSearchCV algorithm was used, and the following list of parameter sets was used (n_estimators: [50, 100, 200, 500, 1000], learning_rate: [0.01, 0.05, 0.1, 0.3], max_depth: [3, 4, 5, 6, 7, 8, 9, 10], subsample: [0.5, 0.7, 0.8, 0.9, 1.0], colsample_bytree: [0.5, 0.7, 0.8, 0.9, 1.0], gamma: [0, 0.1, 0.2, 0.3, 0.4], min_child_weight: [1, 3, 5, 7]).

[0135]

[0136] Example 10. Random forest modeling

[0137] We implemented a random forest framework with 5-fold cross validation using Python's RandomForestClassifier package. The gridSearchCV algorithm was used for hyperparameter tuning, and the following parameter set was used (n_estimators: [50, 100, 200, 500, 1000], max_depth: [3, 4, 5, 6, 7, 8, 9, 10], min_samples_split: [2, 5, 10], min_samples_leaf: [1, 2, 4], bootstrap: [True, False]).

[0138]

[0139] Example 11. Feature Importance Evaluation

[0140] Feature importance values ​​were calculated using the feature_importances_ function in the xgboost package to interpret the impact of each feature on the prediction results. For relative comparison of feature importance, the importance of each feature was expressed as a value divided by the highest feature importance value.

[0141]

[0142] [Experimental Example]

[0143] Experimental Example 1. Multicenter pan-cancer prospective cohort of irAE

[0144] Among 531 patients treated with ICB, 276 patients experienced 68 types of irAEs (see Table 2). Each irAE was labeled based on the affected organ system, including skin, endocrine system, thyroid gland, musculoskeletal system, gastrointestinal system, and neurological system. Based on the severity of the irAE, patients with 3 or more irAE types were additionally labeled as Multiple G>=1, patients with 3 or more Grade ≥2 irAE types were Multiple G>=2, patients with any Grade ≥3 irAE types were Critical, and patients with any Grade ≥2 critical irAE types were Critical. Other labels included Flu-like and Pulmonary, and patients under all irAE categories were designated as Any (see Table 3).

[0145] Type of irAEControlirAE of interestirAE ofnon-interestPruritus255111165Skin rash25587189Fatigue25545231Myalgia25541235Hypothyroidism25532244Pneumonitis25524252Arthralgia25517259Amylase25516260Lipase25516260Enterocolitis25515261Headache25515261Dry mouth25513263Fever25513263Nausea25512264Anorexia25510266Liver enzyme25510266Hyperthyroidism2559267Neuropathy2559267Sweating2559267Adrenal insufficiency2557269Dizziness2557269Edema facial2556270Urticaria2555271Infusion chills2555271Infusion2555271Dermatitis2554272Abdominal pain2554272Vomiting2554272Muscle weakness2554272Creatine phosphokinase elevation2554272Dry eye2554272Lichen planus2553273Pancreatitis2553273Constipation2553273Stomatitis2553273Type I diabetes mellitus2553273Edema limb2553273Hand foot syndrome2552274Paronychia2552274Dysesthesia2552274Cognitive dysfunction2552274Pericarditis2552274Hoarseness2552274Infusion chest2552274Skin hypopigmentation2551275Dry skin2551275Bullous pemphigoid2551275Myositis2551275Exacerbation of rheumatoidarthritis2551275Myopathy2551275Meningoencephalitis2551275Eosinophilia2551275Nephritis2551275Creatinine increased2551275Proteinuria2551275Hematuria2551275Renal thrombotic microangiopathy2551275Blurred vision2551275Retinopathy2551275Tinnitus2551275Hyposmia2551275Sore throat2551275Insomnia2551275Herpes zoster2551275Infusion throat2551275Hypercalcemia2551275Eczema2551275Acute tubular necrosis2551275

[0146]

[0147]

[0148]

[0149] According to Table 4 below, 52% of all cases were labeled Any, while skin was the most frequent irAE type (26%), followed by influenza-like (21%) and multiple (all grades) (18%).

[0150] Type of irAEControlirAE of interestirAE ofnon-interestAny2552760Skin255140136Flu-like255110166Multiple (any grade)25595181Endocrine25583193Gastrointestinal25565211Musculoskeletal25558218Critical25549227Thyroid25546230Multiple (grade >= 2)25544232Neurologic25533243Pulmonary25524252

[0151]

[0152] In addition, multidimensional sequencing was performed on this cohort to identify genetic, molecular, and cellular risk factors for irAEs. RNA sequencing was performed on 531 matched whole blood samples before ICB treatment (PRE) and at the beginning of treatment (EDT) to investigate differential molecular activity and immune cell profiles between patients with and without irAEs and between PRE and EDT.

[0153]

[0154] Experimental Example 2. Identification of neutrophil and immune cell profiles associated with irAE in both PRE and EDT irAE samples.

[0155] Gene expression was analyzed using RNA sequencing for 531 matched whole blood samples before (PRE) and at the beginning of ICB treatment (EDT). Principal component analysis (PCA) was performed to determine whether there were batch effects across organs and collection points. As shown in Figure 1, all samples were well-matched, regardless of organ or collection point.

[0156]

[0157] To construct the model, the entire sample was divided into training and test sets at a ratio of 8:2 based on the incidence of irAEs (training set number = 424, test set number = 107). To capture comprehensive characteristics of neutrophils, neutrophil quantification values ​​were calculated based on gene expression. Neutrophil quantification values ​​were quantified and normalized through single-sample gene set enrichment analysis using the neutrophil-mediated immunity pathway gene set provided by Gene Ontology (http: / / geneontology.org / ).

[0158] As a result of examining the correlation between the neutrophil count and the occurrence of irAE in the training set, as shown in Figure 2, it was confirmed that the neutrophil count was lower in patients who developed irAE, and this tendency was more clearly revealed in the post-treatment (EDT) samples.

[0159]

[0160] In addition, apart from confirming the expression of the neutrophil-mediated immune pathway gene set for the above neutrophil quantitative value confirmation, the expression level of neutrophil marker genes was confirmed, and as a result, as shown in Figure 3, it was significantly lower in the irAE group than in the control group in both PRE and EDT samples (irAE = 137 people, control = 122 people).

[0161] We then characterized irAE-related aberrations at the molecular level, beyond cell counts. To this end, we identified genes with higher or lower expression in irAE samples. As shown in Figure 4 , differential gene expression was primarily characterized by underexpression in the irAE group, which was more pronounced in the EDT samples than in the PRE samples. Pathway enrichment analysis, as shown in Figure 5 , demonstrated that irAE-related gene repression occurred in neutrophil-mediated immunity, as well as neutrophil activation and degranulation, in both the PRE and EDT samples. However, the degree of pathway enrichment was significantly greater for genes identified in the EDT samples. A similar pattern was observed when underexpressed genes were identified in each of the 12 irAE groups compared to the control group, as shown in Figure 6 .

[0162]

[0163] Next, apart from the aforementioned neutrophil quantification and neutrophil marker gene expression levels, we examined the association between irAEs and immune cell types in the training set. As shown in Figure 7, we identified immune cell types that showed significant associations with irAEs both before and after treatment, and this trend was further aggravated in post-treatment (EDT) samples (upper bar: irAEs, lower bar: control).

[0164]

[0165] Experimental Example 3. Establishment and Evaluation of an RNA-Based IrAE Prediction Model

[0166] As confirmed in Experimental Example 2 above, the features associated with irAEs in the training set were confirmed for samples before and after treatment, and the tendency was confirmed to be intensified after treatment (EDT). Based on this, the quantitative values ​​of neutrophils and immune cell profiles (neutrophils, natural killer T cells (NKT), type 1 regulatory T cells (Tr1), type 1 T helper T cells (Th1), induced regulatory T cells (iTreg), central memory T cells (Tcm), CD4) that were significantly associated with the occurrence of irAEs for samples before and after treatment were determined. + Naive T cells (CD4 + A prediction model for irAE occurrence was established using 10 features (FDR value <0.01) of naive T cells, effector memory T cells (Tem), and cytotoxic T cells (Tc).

[0167]

[0168] As a result of verifying the model learned with the training set on the test set, as shown in Fig. 8, before treatment (PRE), the test AUC value of the model created with XGBoost was 0.66, and the test AUC value of the model created with Random forest was 0.67. After treatment (EDT), the test AUC value of the model created with XGBoost was 0.78, and the test AUC value of the model created with Random forest was 0.72. Therefore, it was found that the model created with XGBoost showed better performance than the model created with Random forest. In addition, when the importance of the 10 features was confirmed in the XGBoost model, as shown in Fig. 9, Tc was the most important feature before treatment, and Neutrophil was the most important feature after treatment.

[0169]

[0170] The foregoing description of the present invention is provided for illustrative purposes only. Those skilled in the art will readily appreciate that the present invention can be readily modified into other specific forms without altering the technical spirit or essential characteristics of the present invention. Therefore, the embodiments described above should be understood as illustrative in all respects and not restrictive.

[0171]

[0172] The neutrophil quantitative value or immune cell profile according to the present invention is expected to be useful as a biomarker for predicting the onset of immune-related adverse reactions induced by immunotherapy or predicting responsiveness to immunotherapy, and thus has industrial applicability.

Claims

1. A method for providing information for predicting the onset of an immune-related adverse reaction induced by an immunotherapy agent, comprising: a step of measuring the expression of a gene in a biological sample isolated from a subject; and a step of detecting at least one selected from the group consisting of a neutrophil score and an immune cell profile.

2. In paragraph 1, A method for providing information for predicting the onset of an immune-related adverse reaction induced by an immunotherapy agent, characterized in that the expression of the above gene is measured through one or more methods selected from the group consisting of sequencing, RNA sequencing, and next generation sequencing (NGS).

3. In paragraph 1, The above immune cell profile includes neutrophils, natural killer T cells (NKT), type 1 regulatory T cells (Tr1), type 1 helper T cells (Th1), induced regulatory T cells (iTreg), central memory T cells (Tcm), and CD4 + Naive T cells (CD4 + A method for providing information for predicting the onset of an immune-related adverse reaction induced by an immunotherapy agent, characterized in that the value is a value measuring the amount of one or more selected from the group consisting of naive T cells, effector memory T cells (Tem), and cytotoxic T cells (Cc).

4. In paragraph 1, A method for providing information for predicting the onset of an immune-related adverse reaction induced by an immunotherapy agent, characterized in that the subject is a cancer patient before or after receiving immunotherapy treatment.

5. In paragraph 1, A method for providing information for predicting the onset of an immune-related adverse reaction induced by an immunotherapy agent, characterized in that the biological sample is at least one selected from the group consisting of tissue, cells, whole blood, serum, plasma, saliva, sputum, cerebrospinal fluid, urine, and feces isolated from a subject.

6. In paragraph 1, A method for providing information for predicting the onset of an immune-related adverse reaction induced by an immunotherapy agent, characterized in that the immune-related adverse reaction is at least one selected from the group consisting of skin adverse reactions, endocrine system adverse reactions, thyroid gland adverse reactions, musculoskeletal system adverse reactions, gastrointestinal system adverse reactions, neurologic system adverse reactions, flu-like symptoms, and pulmonary symptoms caused by an immunotherapy agent.

7. In paragraph 1, The method further comprises a step of predicting that the risk of developing an immune-related adverse reaction is high when at least one selected from the group consisting of a neutrophil score, the amount of neutrophils in an immune cell profile, and the amount of cytotoxic T cells in an immune cell profile is lower than that in a control group in a biological sample isolated from a subject, wherein the method provides information for predicting the onset of an immune-related adverse reaction induced by an immunotherapy agent.

8. In paragraph 1, The above method is used to identify natural killer T cells (NKT), type 1 regulatory T cells (Tr1), type 1 helper T cells (Th1), induced regulatory T cells (iTreg), central memory T cells (Tcm), and CD4 among the immune cell profiles in a biological sample isolated from a subject. + Naive T cells (CD4 + A method for providing information for predicting the onset of an immune-related adverse reaction induced by an immunotherapy agent, characterized in that it further includes a step of predicting that the risk of onset of an immune-related adverse reaction is high when the amount of at least one selected from the group consisting of naive T cells, and effector memory T cells (Tem) is higher than that of a control group.

9. In paragraph 1, A method for providing information for predicting the onset of an immune-related adverse reaction induced by an immunotherapy agent, characterized in that the method further comprises a step of predicting the risk of onset of an immune-related adverse reaction induced by an immunotherapy agent through a machine learning-based model by detecting at least one selected from the group consisting of a neutrophil score and an immune cell profile.

10. In paragraph 9, A method for providing information for predicting the onset of immune-related abnormalities induced by an immunotherapy agent, characterized in that the machine learning-based model is at least one selected from the group consisting of XGBoost and random forest.

11. A composition for predicting the onset of an immune-related adverse reaction induced by an immunotherapy agent, comprising an agent for detecting at least one selected from the group consisting of a neutrophil score and an immune cell profile.

12. In paragraph 11, The above immune cell profile includes neutrophils, natural killer T cells (NKT), type 1 regulatory T cells (Tr1), type 1 helper T cells (Th1), induced regulatory T cells (iTreg), central memory T cells (Tcm), and CD4 + Naive T cells (CD4 + A composition for predicting the onset of an immune-related adverse reaction induced by an immunotherapy agent, characterized in that the value is a value measured by the amount of one or more selected from the group consisting of naive T cells, effector memory T cells (Tem), and cytotoxic T cells (Ct).

13. In paragraph 11, A composition for predicting the onset of an immune-related adverse reaction induced by an immunotherapy agent, characterized in that the immune-related adverse reaction is at least one selected from the group consisting of skin adverse reactions, endocrine system adverse reactions, thyroid gland adverse reactions, musculoskeletal system adverse reactions, gastrointestinal system adverse reactions, neurologic system adverse reactions, flu-like symptoms, and pneumonia caused by an immunotherapy agent.

14. In paragraph 11, A composition for predicting the onset of an immune-related adverse reaction induced by an immunotherapy agent, characterized in that the agent for detecting the above neutrophil quantitative value includes a primer or probe that specifically binds to a set of genes of the neutrophil-mediated immunity pathway.

15. In paragraph 11, The agent for detecting the above immune cell profile is neutrophil, natural killer T cell (NKT), type 1 regulatory T cell (Tr1), type 1 T helper T cell (Th1), induced regulatory T cell (iTreg), central memory T cell (Tcm), CD4 + Naive T cells (CD4 + A composition for predicting the onset of an immune-related adverse reaction induced by an immunotherapy agent, characterized in that it comprises a primer or probe that specifically binds to a set of marker genes for one or more immune cells selected from the group consisting of naive T cells, effector memory T cells (Tem), and cytotoxic T cells (Tc).

16. A kit for predicting the onset of an immune-related adverse reaction induced by an immunotherapy agent, comprising a composition of any one of claims 11 to 15.

17. A method for providing information for predicting responsiveness to an immunotherapy, comprising: a step of measuring the expression of a gene in a biological sample isolated from a subject; and a step of detecting at least one selected from the group consisting of a neutrophil score and an immune cell profile.

18. Use of a composition comprising an agent for detecting at least one selected from the group consisting of neutrophil score and immune cell profile for predicting the onset of an immune-related adverse reaction induced by an immunotherapy agent.

19. Use for the manufacture of a preparation for predicting the onset of an immune-related adverse reaction induced by an immunotherapy agent, wherein the preparation detects at least one selected from the group consisting of a neutrophil score and an immune cell profile.

Citation Information

Patent Citations

  • Method of purifying cresols, method of producing novolak resin for photosensitive resin composition and photosensitive resin composition

    KR102066814B1

  • KR20220138828A

Cited By

  • Immune-related adverse reaction marker and kit

    CN122430313A